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Abstract 
Apart from prion protein genotype, the factors determining the host range and susceptiblity for specific transmissible 
spongiform encephalopathy agents remain unclear. It is known that bovine atypical L-BSE can transmit to a range of 
species including primates and humanised transgenic mice. It is important, therefore, that there is as broad an under-
standing as possible of how such isolates might present in food animal species and how robust they are on inter- and 
intra-species transmission to inform surveillance sytems and risk assessments. This paper demonstrates that L-BSE 
can be intracerebrally transmitted to sheep of several genotypes, with the exception of ARR/ARR animals. Positive 
animals mostly present with a cataplectic form of disease characterized by collapsing episodes and reduced muscle 
tone. PrP accumulation is confined to the nervous system, with the exception of one animal with lymphoreticular 
involvement. In Western blot there was maintenance of the low molecular mass and glycoform profile associated with 
L-BSE, irrespective of ovine host genotype, but there was a substantially higher N-terminal antibody signal relative to 
the core-specific antibody, which is similar to the ratio associated with classical scrapie. The disease phenotype was 
maintained on experimental subpassage, but with a shortened survival time indicative of an original species barrier 
and subsequent adaptation. Passive surveillance approaches would be unlikely to identify such cases as TSE suspects, 
but current statutory active screening methods would be capable of detecting such cases and classifying them as 
unusual and requiring further investigation if they were to occur in the field.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
The transmissible spongiform encephalopathies (TSE), 
fatal neurodegenerative diseases of animals, have been 
recognised for nearly three hundred years. Despite sim-
ilar diseases occurring in man (e.g. [1]) the animal TSE 
were not regarded as zoonotic until the emergence in 
1996 of variant Creutzfeldt-Jakob Disease (vCJD), linked 
to bovine spongiform encephalopathy (BSE) [2–4] which 
was first described in cattle in the 1980s [5]. The subse-
quent BSE epidemic, driven by the recycling of the agent 
in feedstuffs, affected nearly 200 000 cattle in the UK and, 
to a lesser extent, elsewhere, particularly in Europe [6]. It 
is thought to have been attributable to a single strain of 
agent [7–9], now referred to as classical BSE (C-BSE).
Following the implication of BSE as the origin of vCJD 
in man, substantial effort and expense has gone into 
ensuring the safety of the animal feed and human food 
chains. It was established through experimental challenge 
that sheep and goats were susceptible to C-BSE [10, 11] 
and a formal component of disease surveillance currently 
requires the classification of all TSE positive small rumi-
nant isolates as “BSE-like” or “non-BSE-like” [EC TSE 
surveillance regulations (999/2001 as amended 36/2005)]. 
This reflects the hypothetical risk that would have been 
posed to the sheep population through exposure to BSE-
contaminated concentrate feeds prior to the banning of 
mammalian protein in mammalian feedstuffs. These con-
cerns have since been reinforced by the identification of 
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two naturally-occurring cases of classical BSE in goats, 
one in France [12] and one in Scotland [13, 14].
Since its introduction in 2001, systematic EU-wide 
active surveillance for TSE in cattle and small ruminants 
[EU reg 999/2001] has resulted in the detection of two 
additional forms of BSE in cattle, commonly referred to 
collectively as “atypical”, that affected mainly cattle eight 
years of age or older (for reviews see [15, 16]). These 
cases were characterised as different from C-BSE, and 
designated H-BSE and L-BSE (also referred to as bovine 
amyloidotic spongiform encephalopathy (BASE) [17]), 
based on molecular features of the disease-associated 
form (PrPSc) of the host PrP, or prion protein, which is 
the marker recognised by all current surveillance tests 
[18, 19]. To date, none of the “atypical” BSE cases diag-
nosed in various countries in cattle (Bos taurus) have 
been reported as clinical TSE suspects, and most cases 
have been identified through the surveillance of fallen 
stock. Given the rarity of these cases, and their wide-
spread geographical distribution it has been speculated, 
but not yet established, that these atypical forms of dis-
ease are genetic in origin and/or arise spontaneously, and 
that they may be the origin of classical BSE [20, 21]. Even 
if there is no evidence of natural spread between animals 
in the field, these variants have been shown (like C-BSE) 
to transmit experimentally into a range of host species.
There is still no robust understanding of what makes 
a particular host susceptible, or a TSE isolate zoonotic 
[22], and it has been demonstrated that atypical BSE can 
transmit to a range of species including primates [23–25] 
and humanised transgenic mice [26, 27]. It is important, 
therefore, that there is as broad an understanding and 
awareness of how such isolates present in food animal 
species, how robust they are on inter- and intra-species 
transmission, and that they are characterised as fully as 
possible to assist with the maintenance of robust surveil-
lance sytems and the assessment of risk to both human 
and animal health.
The susceptibility of sheep to scrapie and BSE is 
strongly influenced by different polymorphisms of the 
PRNP gene that encodes for prion protein (PrP), with 
polymorphisms at codons 136 (A or V), 141 (L or F), 
154 (R or H) and 171 (R, Q or H) demonstrated to be of 
major importance (for recent review, see [16]). There-
fore, when investigating the transmissibility to sheep of 
any non-ovine isolates, it is important to consider a range 
of host genotypes, to account for potentially variable 
susceptibility.
This paper presents a study of the transmissibility and 
characterisation of L-BSE in sheep of various genotypes, 
and assesses whether the current surveillance require-
ments would be sufficient to detect and classify such 
cases if they were to occur in the field.
Materials and methods
Animal experimentation
All inoculations were carried out under general anaes-
thesia and in accordance with the United Kingdom (UK) 
Animal (Scientific Procedures) Act 1986, under license 
from the UK Government Home Office (Project licence 
no: 70/6781). Such license is only granted following 
approval by the internal Animal and Plant Health Agency 
(APHA) ethical review process as mandated by the Home 
Office.
Inoculum (10% w/v brain homogenate in normal 
saline) was prepared from an Italian L-BSE field case 
(141387/02), and stored at −80 °C prior to use. TSE nega-
tive bovine brain, previously sourced from New Zealand, 
was used as a negative control inoculum with the kind 
agreement of the New Zealand authorities.
All recipient sheep were supplied from the Defra New 
Zealand-derived flock [28] and were 4–6  months old at 
inoculation. For the primary passage, five sheep of each 
of five PRNP genotypes A136F141R154Q171/AFRQ, ARR/
ARR, ARQ/ARQ; ARQ/VRQ, VRQ/VRQ [the amino 
acid at codon 141 (L in wild-type, F when polymorphic) 
is only indicated when it deviates from the wild type] 
were inoculated intracerebrally (IC) with 1 mL of inocu-
lum. All sheep were housed for the duration of the study 
in biosecure accommodation that had never previously 
housed any TSE affected animals, and was fully cleaned 
and disinfected (20% Chloros) prior to use. Each pen had 
separate equipment and personal protective clothing. 
Animals were handled and observed daily as part of rou-
tine husbandry procedures, until clinical disease devel-
oped, or until a pre-determined experimental endpoint 
of approximately 5 years post-inoculation (pi). A further 
two sheep of each genotype were inoculated with nega-
tive control brain material and housed in the same build-
ing but separated by a concrete wall so that they only 
shared the same air space.
Following the identification of the first positive ani-
mals in the primary passage study, inoculum for sub-pas-
sage was prepared from two positive sheep, one AFRQ/
AFRQ and one ARQ/VRQ. These animals were selected 
to reflect the two slightly different clinical presentations 
that had been observed in the animals that had suc-
cumbed to disease at that time. Each ovine source was 
used to inoculate five AFRQ/AFRQ and five ARQ/VRQ 
recipients. Both inoculation groups were housed in sepa-
rate pens, similar to the primary passage study.
Clinical monitoring
All sheep were examined neurologically prior to inocu-
lation, then monitored daily during routine husbandry 
procedures (feeding, bedding changes) and weighed 
monthly. Weight loss prior to cull was expressed in 
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percent of the previous body weight determined prior to 
weight loss. Routine clinical examinations [29] were con-
ducted quarterly from 8 months pi (primary passage) and 
6  months pi (sub-passage), increasing to weekly for any 
formal suspect animal. Additional neurological examina-
tions [30] were conducted prior to cull (with the excep-
tion of the first culled sheep, which was last examined 
2  months prior to death), or if animal husbandry staff 
noted any signs suggestive of a neurological disease. 
Inoculated animals were also monitored during the day-
time by CCTV.
The clinician was unaware of the genotype of specific 
challenged animals but the identity of the control group 
in the primary passage was known because these animals 
were always examined first.
Clinical end-point was considered to have been 
reached when sheep displayed progressive abnormalities 
in sensation (positive scratch test with or without alo-
pecia, absent menace response) and movement (ataxia, 
limb weakness, tremor). In addition, the display of signs 
likely to result in permanent recumbency or death, such 
as seizures or collapse not triggered by human interven-
tion, was considered to be a clinical end-point, which 
resulted in cull using quinalbarbitone sodium (Somu-
lose, Arnolds) intravenously. Animals, including the con-
trols, that remained healthy throughout the study, were 
killed at the end of the study. One control animal from 
each genotype pair was killed after the last animal in the 
matched genotype challenged group succumbed, and the 
others were kept until the endpoint of the study, approxi-
mately 5 years post challenge.
Pathology and immunohistochemistry
Postmortem, the whole brain was removed from each 
sheep and hemisected longitudinally. One half of the 
brain was placed into 10% formal saline for histology, and 
the other half stored at −80 °C. Samples representative of 
the trigeminal, nodose, cranial cervical, stellate and coe-
liaco-mesenteric ganglia, the lateral retropharyngeal and 
mesenteric lymph nodes, the recto-anal mucosa-associ-
ated lymphoid tissue (RAMALT), the spleen, the distal 
ileum (with Peyer’s patches) and the extraocular muscles 
were also collected into 10% buffered formalin.
All brain tissue was routinely fixed, blocked to rep-
resent the major levels of the neuraxis and processed, 
sectioned and stained with haematoxylin and eosin as 
described in detail elsewhere [31]. Immunohistochemical 
detection of PrPSc was performed on adjacent sections 
from the same brain blocks, and on the other tissues, 
using mouse monoclonal antibody (mAb) 2G11 (ABD 
Serotec), raised against the ovine PrP peptide sequence 
146-R154 R171-182, as described in detail elsewhere [32]. 
Sections from the obex were also immunolabelled with 
the mAb P4, which can be used to discriminate ovine BSE 
from scrapie [33]. Vacuolation and immunohistochemis-
try profiles were created using standard subjective meth-
ods as previously described [31, 34] in which the severity 
of vacuolar lesions, or the type of PrP immunolabelling, 
is assessed in a standard range of precise neuroanatomi-
cal areas. Some modifications were made to the original 
method [34] to accommodate the range of morphological 
PrPSc immunolabelling types first identified in atypical 
scrapie.
Western immunoblot
All samples were subjected to the BioRad TeSeE™ West-
ern immunoblot (according to the manufacturer’s instruc-
tions) and, run on two replicate gels (18.75  mg tissue 
equivalent per well). The primary antibodies were Sha31 
(prepared according to the kit protocol) and P4 (0.2  µg/
mL, RIDA®, r-Biopharm). The signal was developed 
using ECL detection blotting reagents, detected and ana-
lysed with exposure times of 1 and 10 min using Biorad 
Quantity One vers. 4.6.9 software on Fluor-S Max imager. 
Where Sha31 and P4 antibody ratio calculations were per-
formed the images for both antibodies were obtained at 
the same time and 1 min exposure times were used.
The original bovine donor animal, a classical bovine 
BSE field case, an ovine classical scrapie field case, an 
experimentally transmitted ovine BSE [35] and a negative 
ovine sample were used as controls alongside the primary 
passaged samples. The same field case bovine BSE and 
ovine scrapie controls were used as controls alongside 
the sub-passaged samples.
Western immunoblots were also performed on ret-
ropharyngeal lymph node from the single primary pas-
sage pre-clinical VRQ/VRQ animal which displayed 
peripheral tissue involvement. Brain tissue from the same 
animal, lymphoid and brain tissue from experimentally 
transmitted ovine classical BSE and brain tissue from the 
field case bovine BSE and field case ovine BSE were used 
as comparative controls.
Elisa
Samples from all positive animals from the primary pas-
sage were subject to four commercially available ELISA 
tests—IDEXX Herdchek™ with bovine conjugate, IDEXX 
Herdchek™ with ovine conjugate, BioRad TeSeE™ and 
BioRad S&G™. For each test, samples were extracted and 
the tests carried out in accordance with the manufactur-
ers’ instructions.
Results
Details of all inoculated animals can be found in Table 1. 
There was a wide range of overlapping incubation peri-
ods for each affected genotype in the primary passage.
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The survival periods for the sheep in the sub-passage 
study were substantially shorter than those of the donor 
animals.
Using the two-sample Kolmogorov–Smirnov tests of 
the equality of distributions, pairwise comparison of 
the sub-passage groups revealed that the survival period 
in the ARQ/VRQ homologous transmission group was 
significantly different to those of the other three groups 
(ARQ/VRQ donor to AFRQ/AFRQ recipient: p = 0.007; 
AFRQ/AFRQ donor to AFRQ/AFRQ recipient: p = 0.05; 
AFRQ/AFRQ donor to ARQ/VRQ recipient: p =  0.05.) 
The ARQ/VRQ donor into AFRQ/AFRQ recipient group, 
and the AFRQ/AFRQ donor into the ARQ/VRQ recipi-
ent group were also significantly different from each 
other (p = 0.05).
Clinical observations
The 10 control animals inoculated with normal brain 
survived to the relevant endpoint of the study; three 
(one AFRQ/AFRQ, one ARQ/ARQ and one ARQ/VRQ) 
were killed after the last challenged animal in the rel-
evant challenge group succumbed to clinical disease, 
at 1678  ±  20  days post challenge (dpi). Neurological 
signs indicative of a vestibular disease were seen in one 
sheep (39/13, AFRQ/AFRQ) from 1376 dpi. A positive 
scratch test [29] was displayed irregularly by seven sheep 
between 915 and 1681 dpi attributable to hay in the fleece 
and/or lesions suggestive of Chorioptes mange. Neither 
wool loss nor weight loss was recorded in any of the con-
trol animals prior to cull. The remaining seven control 
animals were culled at 1978 ± 1 dpi.
From the primary passages, only two VRQ/VRQ ani-
mals and the five ARR/ARR animals survived to the 
pre-determined cull point at approximately 5 years post 
challenge. None of the ARR/ARR sheep displayed signs 
suggestive of a neurological disease, but both VRQ/
VRQ sheep inconsistently displayed fore limb hyperme-
tria and circled when blindfolded, from 1225 and 1713 
dpi respectively. Both sheep were considered clinically 
healthy at cull. At post-mortem, one of the VRQ/VRQ 
animals (48/13) was found to be positive by all diagnostic 
methods, while the other clinically normal animals were 
negative by all tests.
One AFRQ/AFRQ sheep developed changes in behav-
ior and mental status (confusion, separation from others, 
pica) from 860 dpi and subsequent ataxia, hypermetria, 
circling and loss of balance when blindfolded, but no 
weight loss. This sheep was culled at 867 dpi as a TSE sus-
pect, but TSE was not confirmed by postmortem testing.
In the primary passage study, two clinical syndromes 
were described based on the major presenting clini-
cal sign (Table  2). Pruritic behaviour (rubbing, scratch-
ing and nibbling itself ) resulting in wool loss and later 
ataxia, which was indistinguishable from the pruritic 
form of classical scrapie, or experimental ovine classical 
BSE [35] was displayed by two sheep. These sheep also 
presented with a positive scratch test that could later be 
elicited by merely applying firm pressure on the back 
(see Additional file  1: pruritic form). More frequently, 
affected animals presented with a cataplectic form of dis-
ease, characterized by collapsing episodes with reduced 
muscle tone, often with low head carriage and initially 
triggered by lifting of the head or more stressful events 
(e.g. foot trimming, restraint for clinical examinations), 
although in the later stages this occurred during feeding 
time or in the absence of any obvious stimulus. Initially 
Table 1 Summary of inoculation outcomes with survival times and rates
a Preclinical animal, detected at end of study cull (not included in mean survival time calculation).
b Animals used as donors for the sub-passage study.
c Intercurrent disease loss.












Primary VRQ/VRQ 4/5 1183, 1337, 1439,1963a, 1320 ± 129 1964
VRQ/ARQ 5/5 803b, 864, 957, 1056, 1389 1014 ± 231
ARQ/ARQ 5/5 956, 959, 1186, 1531, 1649 1256 ± 321
AFRQ/AFRQ 4/5 1186b, 1236, 1267, 1334 1256 ± 62 867c
ARR/ARR 0/5 2001 ± 3
Subpassage: Donor 
ARQ/VRQ
ARQ/VRQ 5/5 433, 454, 462, 478, 478 461 ± 19
AFRQ/AFRQ 5/5 503, 505, 527, 552, 552 528 ± 24
Subpassage:Donor 
AFRQ/AFRQ
ARQ/VRQ 5/5 461, 488, 496, 501, 531 495 ± 25
AFRQ/AFRQ 5/5 473, 519, 520, 520, 539 514 ± 25
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these episodes were usually very brief, with loss of mus-
cle tone in the limbs causing sheep to drop suddenly to 
the ground but get up again immediately. With disease 
progression, complete loss of muscle tone led to lateral 
recumbency and a complete lack of response, suggestive 
of narcolepsy (see Additional file  2: cataplectic form). 
Pruritus was not evident in these cases although some 
displayed a positive scratch test the significance of which 
was difficult to interpret given the similar observations in 
the control sheep.
Table 2 Clinical syndromes in sheep challenged with L-type BSE
a Cataplexy is spontaneous collapse due to complete atonia of skeletal muscles, often associated with narcolepsy (disorder of normal sleep mechanism, usually 
excessive sleep). The latter may also be a feature in affected L-type BSE-inoculated sheep but is difficult to diagnose.
b Animals selected for subpassage.
Passage Animal ID Genotype Syndrome Other neurological and behavioural signs
Primary 456/11 VRQ/VRQ Cataplectica None
113/12 Cataplectic Ataxia
167/12 Cataplectic Head tremor, occasionally horizontal nystagmus during 
collapsing episodes, teeth grinding
1591/10b VRQ/ARQ Undefined, (possibly pruritic) Seizure-like episode, positive scratch test
58/11 Cataplectic Dullness, ataxia, loss of balance
4/12 Cataplectic Head tremor, ataxia
140/11 Cataplectic Positive scratch test, head tremor, ataxia
267/11 Cataplectic Positive scratch test, ataxia
63/11 ARQ/ARQ Pruritic Dullness, head tremor, ataxia, loss of balance
3/11 Cataplectic Positive scratch test, ataxia, loss of balance
182/12 Pruritic Positive scratch test, ataxia, loss of balance
3/13 Cataplectic Dullness, teeth grinding, absent menace response, ataxia, 
loss of balance
455/11 Cataplectic Positive scratch test, ataxia
98/11b AFRQ/AFRQ Cataplectic Ataxia
457/11 Cataplectic Head tremor, ataxia
26/12 Cataplectic Head tremor, ataxia, loss of balance
112/12 Cataplectic Positive scratch test, head tremor, ataxia
Subpassage: donor VRQ/VRQ 112/14 ARQ/ARQ Cataplectic Dullness, positive scratch test, absent menace response, 
head tremor, ataxia, loss of balance, circling
120/14 Cataplectic Positive scratch test, absent menace response, head 
tremor, ataxia, circling, teeth grinding
119/14 Cataplectic Positive scratch test, head tremor, ataxia, loss of balance, 
circling
107/14 Cataplectic Absent menace response, head tremor, ataxia, teeth 
grinding
108/14 Cataplectic Head tremor, ataxia, circling
79/14 ARQ/VRQ Cataplectic Positive scratch test, head tremor, loss of balance
78/14 Cataplectic Positive scratch test
76/14 Cataplectic Head tremor
6/14 Cataplectic Ataxia
73/14 Cataplectic Absent menace response, head tremor, loss of balance
Subpassage: donor AFRQ/AFRQ 109/14 ARQ/ARQ Cataplectic Absent menace response, head tremor
110/14 Cataplectic Absent menace response, head tremor, ataxia
111/14 Cataplectic Absent menace response, head tremor, ataxia
118/14 Cataplectic Absent menace response, head tremor, ataxia
77/14 Cataplectic Absent menace response, ataxia
81/14 ARQ/VRQ Cataplectic Head tremor, loss of balance
80/14 Cataplectic Head tremor, teeth grinding
117/14 Cataplectic Head tremor, ataxia, loss of balance
82/14 Cataplectic Head tremor, ataxia, loss of balance, circling
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The clinical classification was equivocal in the first 
sheep culled with confirmed TSE (1591/10) because it 
displayed a positive scratch test without any other signs 
of pruritus at a time when none of the controls showed 
this sign but was culled after being observed dropping to 
the floor with limb muscle contraction, similar to a sei-
zure and contrary to the atonia seen in the cataplectic 
form (see Additional file 3: seizure-like disorder).
Weight loss of 2.1–14.6% (mean 6.8%) prior to cull was 
recorded in 15 primary passage sheep (88%).
In the subpassage study, one ARQ/VRQ sheep inocu-
lated with the AFRQ/AFRQ donor inoculum was found 
dead at 461 dpi without any premonitory signs being 
observed. Minor weight loss (1.7%) was present prior to 
death. This sheep was confirmed positive by postmortem 
examination.
All the other subpassage animals, regardless of the 
donor/recipient combination, presented with the cata-
plectic syndrome. Five sheep of one inoculation group 
also displayed a positive scratch test, probably attribut-
able to the chorioptic mange that was diagnosed in this 
group.
Nine of the 19 subpassage recipients (47%) that suc-
cumbed to clinical disease lost weight prior to cull 
(0.8–20.4%, mean 7.0%). All 19 sheep were positive by all 
diagnostic methods.
Pathology
Vacuolar pathology consistent with TSE was present in 
all positive cases, with a distribution in the brain that was 
similar in all L-BSE recipient genotypes (Figure 1) regard-
less of the clinical presentation or passage history, and 
distinctly different from animals of the same genotypes 
infected with classical scrapie or C-BSE [31]. There was 
limited vacuolation in the brainstem, and the intensity 
of vacuolation increased markedly in more rostral areas, 
with high scores for the thalamic areas, the basal ganglia 
and the cerebral cortex (frontal lobes).
Widespread immunolabelling was present at all lev-
els of the brain and spinal cord with antibody 2G11. In 
every case, the predominant labelling type was fine par-
ticulate in the neuropil (Figure  2), with intraneuronal 
and glial labelling also present, and some linear forms 
and small aggregates. Stellate forms were rarely seen. 
All of the intraneuronal labelling, and most of the neu-
ropil labelling was lost with antibody P4 (Figures 2A and 
B), which would be diagnostically consistent with a dis-
criminatory interpretation of “BSE-like” [33]. Distinc-
tive perineuronal labelling was seen in the basal ganglia 
(Figure 2D). Intracellular labelling was also present in the 
oligodendrocytes.
Detailed mapping using 2G11 revealed no obvious dif-
ference in immunolabelling patterns between animals of 
different genotypes or clinical presentation groupings. Fig-
ure  3 shows the mapping of labelling type distribution in 
one case (455/11) as representative of the central nervous 
system pathology seen in all the positive sheep in this study. 
The one VRQ/VRQ sheep that was identified as pre-clini-
cally affected at the 5-year cull point (48/13) demonstrated 
positive immunolabelling throughout the brainstem, but 
was negative in the cerebellum and cortical regions. The 
immunolabelling patterns identified in this case were simi-
lar to those seen in the other positive animals, but with the 
addition of stellate forms in several neuroanatomical nuclei.
A range of peripheral tissues from each case was sys-
tematically screened by IHC (Table  3). In seventeen of 
the eighteen positive animals, no immunoreactivity was 
detected in liver, spleen, lymph nodes, distal ileum or 
RAMALT. Labelling was consistently seen in the neu-
ronal cell bodies of the trigeminal and nodose ganglia, 
but not in the cranial cervical or stellate ganglia, or the 
coeliaco-mesenteric plexi. Labelling of the muscle spin-
dles was seen consistently, and in some cases, occasional 
labelled myocytes were also observed.
In the one pre-clinical VRQ/VRQ animal, there was 
positive labelling present in all the lymphoid tissues 
examined, together with the enteric nervous system and 
the coeliaco-mesenteric ganglion in addition to the mus-
cle spindles (Figures  2I  and J). Unlike the other cases, 
labelling with P4 was retained in the brainstem, which 
would be diagnostically consistent with a discriminatory 
interpretation of “scrapie-like”. However, P4 labelling was 
lost in the lymphoid tissue, which would be consistent 
with a BSE-like interpretation.
The vacuolar profiles (Figure  1B) and immunohisto-
chemical PrP distribution patterns in the sub-passage 
animals (not illustrated) were the same as those of the 
donor animals.
No histological lesions or PrP accumulation were 
detected in any of the control sheep.
Biochemistry
All the clinical cases from the primary passage tested 
positive using all four different ELISA formats (Table 4).
The L-BSE recipients that succumbed to clinical disease 
were subjected to comparative Western immunoblotting 
(Figures 4A–D). The samples were grouped according to 
genotype—those which were ARQ/ARQ, with either F or 
L at codon 141 (Figures 4A and B) and those which car-
ried one or two VRQ alleles (ARQ/VRQ or VRQ/VRQ) 
(Figures 4C and D).
The donor profile exhibited the three visual charac-
teristics that are associated with L-BSE: a low molecu-
lar mass migration, a glycoform ratio where the di- and 
mono-glycosylated bands contain a more equal propor-
tion of PrPSc than classical BSE when detected with the 
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core mAb (Sha31), and a lack of detection with the N-ter-
minal mAb (P4).
In affected animals the overall trend observed was 
maintenance of the low molecular mass and a glycoform 
profile similar to L-BSE or classical scrapie, irrespective 
of genotype (representative cases are illustrated in Fig-
ure 4 and Additional file 4), although in one VRQ/VRQ 
sheep (167/12; Lane 8, Figures 4C and D) the molecular 
Figure 1 Vacuolar lesion profiles. A Primary transmission of bovine L-BSE to sheep. Square = AFRQ/AFRQ recipients (n = 4), diamond = ARQ/
ARQ recipients (n = 5), triangle = ARQ/VRQ recipients (n = 5), circle = VRQ/VRQ recipients (n = 3). B Subpassages of ovine L-BSE to sheep. 
Square = ARQ/VRQ recipient, ARQ/VRQ donor (n = 5), diamond = AFRQ/AFRQ recipient, AFRQ/AFRQ donor (n = 5), triangle = ARQ/VRQ recipient, 
AFRQ/AFRQ donor (n = 5), circle = AFRQ/AFRQ recipient, ARQ/VRQ donor (n = 5). X-axis: brain areas from Ligios et al. [31]. 1–11 brainstem areas, 12, 
13 the cerebellum, 15–19 midbrain and thalamus, 20–22 the basal ganglia and frontal cortex. Y-axis: mean vacuolation score. Vacuolation is consist-
ently greater in the more rostral brain areas than in the brainstem, regardless of genotype or passage history, with a slight but consistent increase in 
the intensity of vacuolation throughout the brain following sub-passage.
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Figure 2 Immunohistochemistry representative of ovine L-BSE. All figures illustrate labelling with mAb 2G11, except B. Neuronal and par-
ticulate labelling is present in the DNV with mAb 2G11 (A), but absent with mAb P4 (B) (case 455/11). Particulate labelling and small aggregates are 
abundant in many areas, such as the thalamic nuclei (C) (case 1591/10). Perineuronal labelling in the putamen is a consistent and striking feature 
of ovine L-BSE (D) (case 1591/10), as is intracellular labelling of oligodendrocytes, seen here in the spinocerebellar tract (rostral medulla) (E) (case 
58/11). Intraneuronal labelling is also present in the DRG (F) (case 4/12). Heavy labelling in muscle spindles is also visible (G) (case 267/11) and also 
in occasional myocytes (H) (case 98/11). Labelling was also present in the LRS (I) and ENS (J) of one VRQ/VRQ recipient (case 48/13).
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Figure 3 Schematic non-quantitative representation of the neuroanatomical distribution of PrP immunolabelling. Every area that was 
positive contained particulate labelling, so this has been omitted from the figure to make the presence and distribution of the other labelling types 
easier to see. This map is based on a single case (case 455/11) as representative of all positive animals.
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mass migration of the unglycosylated band was slightly 
higher than for the other cases. There was a substantial 
increase in the detection by the N-terminal antibody 
relative to the bovine L-BSE donor, thereby giving an 
antibody detection ratio for the recipient animals closer 
to that obtained with classical scrapie. This was more 
consistent in ARQ/ARQ animals (Figure  4B; Additional 
file 4) than in those with valine at codon 136. This molec-
ular profile was maintained on sub-passage (Figure  5; 
Additional file 5).
In two VRQ/VRQ animals the molecular mass of the 
unglycosylated band was higher than that observed in the 
other L-BSE samples (Figures 4C (lane 8) and  6). These 
samples also showed strong affinity with P4. In contrast 
to all other affected animals, one of these VRQ/VRQ 
sheep (48/13) had lymphoid tissue involvement showing 
a molecular profile with overall higher molecular mass 
for each band compared to the brain samples and was 
similar, but not identical, to the profile observed in the 
LRS of sheep affected with classical BSE (Figure 6; Addi-
tional file 6). However, strong detection with mAb P4 was 
still evident in contrast to ovine classical BSE where mAb 
P4 detection was absent (lymphoid tissue) or markedly 
reduced (brain tissue). On this blot, the brain tissue from 
the L-BSE case had a molecular mass migration similar 
to the classical scrapie control when detected with Sha31.
Discussion
L-BSE can transmit experimentally, generally by the 
intracerebral route, to a wide range of hosts. These 
include cattle [36–39], sheep [40–42] and this report, 
lemurs [43], macaques [23, 24], hamsters [25, 44, 45] and 
transgenic mice overexpressing bovine, ovine or human 
PrP [20, 25–27, 39, 42, 44, 46–48]. In contrast to classical 
BSE, L-BSE does not transmit to wild type [20] Spiropou-
los and Simmons, unpublished data] or transgenic mice 
that overexpress murine PrP [45, 47], although excep-
tions have been reported [20].
There is evidence that, unlike classical BSE [49], L-BSE 
[20, 25, 42, 44, 45, 47], and H-BSE [21, 47, 50] do not 
always remain stable after intra- or inter-species experi-
mental transmission. In some of these transmissions a 
phenotype shift from both L-BSE and H-BSE towards 
C-BSE has been reported [42, 47], on occasions only 
after sub-passage [25, 44, 45]. Such phenotype shifts 
have also been observed with other animal TSEs [46, 51].
The present study suggests that L-BSE remains stable 
on serial passage through sheep with a partial phenotype 
shift, associated with overt lymphoreticular involvement, 
observed only in one animal. The observation of a BSE-
like labelling pattern in the LRS of this sheep, together 
with the biosecurity measures that were in place, and the 
absence of similar observations in any of the other VRQ/
VRQ sheep, including the two genotype matched con-
trols, would argue against the otherwise “scrapie-like” 
phenotype in this sheep being attributable to infection 
with extraneous classical scrapie.
The disease phenotype observed after intracerebral 
inoculation of sheep with L-BSE does not resemble any 
previously known TSE in this species, but is very con-
sistent regardless of ovine host PrP genotype. The two 
animals selected for sub-passage were chosen because 
of differences in clinical presentation, most notably that 
one (1591/10) was positive on the scratch test, while the 
other one (98/11) was not. This was not in itself sufficient 
for them to be considered as different phenotypes, and all 
other phenotypic parameters in these animals were the 
same, but they represented the only diversity seen at that 
time in the study. The predominant clinical cataplectic 
syndrome reported in the primary challenge animals was 
present in all of the animals challenged in the subpas-
sage study, regardless of which donor was used. All other 
Table 4 Comparative ELISA results for primary challenge animals
a Small ruminant brain conjugate concentrate.
b Bovine brain conjugate concentrate.
c Sheep and goat.
d Clinical cases only. The pre-clinical VRQ/VRQ is not included.
OD (±SD)
IDEXX Herdchek BSE/Sc EIA BioRad
SRB-CCa CCb S&Gc TeSeE
Ovine L-BSE primary challenge (all genotypes) (N = 17d) 2.61 (±0.024) 2.62 (±0.031) 2.68 (±0.057) 2.67 (±0.062)
Ovine C-BSE 2.636 2.668 2.631 2.661
Ovine scrapie 2.632 2.672 2.599 2.635
Ovine negative 0.022 0.026 0.029 0.036
Bovine L-BSE 2.630 2.668 0.063 2.617
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Figure 4 WB images from primary passage samples. A and B Nine representative recipients, homozygous for alanine (codon 136) detected by 
Sha31 (A), or P4 (B). (Lane 1, 63/11; lane 2, 3/11; lane 3, 457/11; lane 4 26/12; lane 5 112/12; lane 6, 182/12; lane 7, 3/13; lane 8, 98/11; lane 9, 455/11; 
AB + , donor bovine L-BSE; B + , bovine C-BSE; S + , ovine Scrapie; BS + , experimental ovine CBSE; S-, negative sheep; M, molecular mass markers. 
A 1 min exposure, B 10 min exposure). C and D Eight representative recipients homozygous or heterozygous for valine (codon 136), detected 
by Sha31 (C) or P4 (D), (Lane 1, case 1591/10; lane 2, case 58/11; lane 3, 140/11; lane 4, 267/11; lane 5, 456/11; lane 6, 113/12; lane 7, 4/12; lane 8, 
167/12; markers and controls as for A and B. C 1 min exposure, D 10 min exposure). There is low molecular mass migration of the unglycosylated 
band (arrow), similar to that of the donor bovine L-BSE (AB+), for all but one of the ovine recipients (VRQ/VRQ Lane 8 C, D) regardless of genotype. 
Similar di-;mono-glycosylated band ratios are also seen in all cases when detected by mAb Sha31 (see Additional file 4). All recipient samples, 
irrespective of genotype, are also detected with mAb P4 (B, D). In contrast the donor L-BSE case (AB+) is not. Following extraction with a Proteinase 
K digestion step, may contain a mixture of varying molecular mass fragments, partly due to multiple cleavage sites and variability in resistance of 
PrPSc to the concentration of the enzyme. The two additional lower bands observed in these profiles are regularly observed in diagnostic samples 
processed in this way. For diagnostic analysis they are disregarded. Only the standard three bands pertaining to the di, mono and un-glycosylated 
forms of PrPSc are considered relevant.
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phenotypic characteristics were also the same, indicating 
the presence of a single strain, stable on subpassage.
The substantial reduction in survival time between the 
primary challenges and the subpassages is indicative of 
an initial transmission barrier between cattle and sheep. 
In the absence of any other phenotypic differences the 
differences in survival time between the different recipi-
ent genotype groups following subpassage is most likely 
an effect of host genotype.
There is no data available on whether this species adap-
tation might alter the host range or virulence of the iso-
late, as has been reported previously for classical BSE 
[52–55]. Previous reports on the transmission of L-BSE 
to sheep have only described the inoculation of animals 
that are ARQ/ARQ [40, 41] or ARQ/ARR [41]. This pre-
sent study extends the range of sheep genotypes inocu-
lated experimentally, to include the VRQ, and AFRQ 
haplotypes. In contrast to the unusual but consistent 
clinical signs reported here, no specific neurological signs 
have been described in the other studies.
Certain phenotypic parameters, such as survival times, 
vacuolation profiles and PrPSc distribution patterns are 
not directly comparable between different species. How-
ever, Western blots are more specific to each TSE agent 
and are generally less affected by the host species.
In this study the WB profiles indicate that the molecular 
mass migration and glycoform ratio of the L-BSE donor iso-
late remained unchanged after passage in ARQ/ARQ sheep, 
regardless of the codon 141 polymorphism, in agreement 
Figure 5 WB for ARQ/VRQ subpassage recipients. A Sha31 and P4 blots of the ARQ/VRQ donor and its ARQ/VRQ recipients. (Lane 1, case 
1591/10 (ARQ/VRQ Donor), Lane 2, case 6/14; Lane 3, case 73/14; Lane 4, case 76/14 Lane 5, case 78/14; Lane 6, case 79/14 M, Molecular marker; B+, 
Bovine BSE; S+, Classical Ovine Scrapie. This panel comprises a mixture of 1 and 10 min exposures). B Sha31 and P4 blots of the AFRQ/AFRQ donor 
and its ARQ/VRQ recipients (Lanes 1 and 2, case 98/11 (AFRQ/AFRQ Donor); Lane 3, case 80/14; Lane 4, case 81/14; Lane 5, case 82/14; Lane 6, case 
75/14; M, molecular marker; S+, classical ovine scrapie; B+, bovine BSE. This panel comprises a mixture of 1 and 10 min exposures). In contrast the 
donor L-BSE case (AB+)molecular characteristics described for primary passage (Figure 4; Additional files 4 A–E) are retained on subpassage for all 
recipient animals regardless of the donor.
Figure 6 WB of brain and LRS from 48/13 (the VRQ/VRQ recipi-
ent with LRS involvement). A Detection with mAb Sha31; B detec-
tion with mAb P4. (M, molecular markers; B+, bovine C-BSE control; 
S+, ovine classical scrapie control; Lane 1, ovine C-BSE brain; Lane 
2, ovine C-BSE lymphoid tissue; Lane 3, ovine L-BSE lymphoid tissue 
(case 48/13); Lane 4, ovine L-BSE brain (case 48/13). 1 min exposure). 
The lymphoid tissue from the ovine C-BSE sample (lane 2) and L-BSE 
recipient (lane 3) show similar but not identical molecular profiles to 
each other with an overall higher mass migration pattern. However 
only the L-BSE sample is detected by mAb P4. The ovine C-BSE brain 
sample exhibits the expected profile characteristics of a low molecu-
lar mass migration, predominant diglycosylated band and mimimal 
detection with mAb P4. The ovine L-BSE brain sample (lane 4) exhibits 
a molecular mass migration that is higher than expected when 
compared to the primary and sub passaged results (Figures 4 and 5), 
appearing similar to the ovine scrapie control. However, the equal 
intensity of di and monoglycosylated bands can be observed. The 
sample was also detected by mAb P4.
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with those reported for other ARQ/ARQ L-BSE ovine chal-
lenges. In addition we have observed an increased reactiv-
ity with the N-terminal antibody which is not reported in 
other ovine L-BSE transmissions [40, 41]. This particular 
characteristic, normally associated with classical scrapie, is 
also observed on transmission of classical BSE to sheep but 
seen as a more gradual N-terminal antibody detection that 
increases after serial subpassage [56]. It is possible that on 
the cross species transmission the atypical forms of BSE 
drive conversion of host PrPc to a form more closely resem-
bling classical scrapie faster than classical BSE does.
Other host genotypes result in more variable Western 
blot characteristics, as demonstrated by the molecular 
mass migration shift towards a scrapie profile seen in two 
of the four VRQ/VRQ animals in this study and in one of 
the ARQ/ARR animals reported elsewhere [41].
Therefore it can be assumed that the species dependent 
phenotypic parameters, with the possible exception of 
survival time, which may be prolonged during interspe-
cies transmission as a result of the transmission barrier, 
are specific for the L-BSE phenotype in sheep. However, 
concrete evidence that the strain identity has not changed 
during passage of the agent in sheep can be obtained by 
comparing bovine and ovine L-BSE sources after bioassay 
in mice. These bioassays are currently ongoing and will 
be reported separately.
There is an apparent susceptibility effect of host geno-
type which mirrors that seen for ovine C-BSE, with ARR/
ARR sheep appearing most resistant, and with longer 
incubation periods associated with VRQ/VRQ ani-
mals [57–59]. This is not surprising as ovine PrP poly-
morphisms play an important role not only in classical 
scrapie, where their effect on susceptibility was first iden-
tified, but also in atypical or Nor98 scrapie. It is reason-
able to assume that PrP polymorphisms in sheep would 
influence susceptibility, and in some cases phenotype, to 
almost any TSE exposure/challenge in these species.
The absence of detectable PrP in lymphoid tissues in 
37/38 positive animals, and the involvement of peripheral 
ganglia and muscle spindles concurs with the peripheral 
tissue distribution of L-BSE in cattle. This differs from the 
widespread lymphoreticular involvement seen in sheep 
challenged with C-BSE either orally [58] or following 
intracerebral inoculation ([60], Simmons, unpublished 
observations) and suggests that L-BSE affected ani-
mals are unlikely to readily disseminate the agent in the 
environment.
The identification of LRS involvement in one inocu-
lated VRQ/VRQ animal, in which there was also stellate 
PrP deposition in the brain, might suggest the emer-
gence of a new phenotype as a result of this interspecies 
transmission, or a stochastic event. To resolve this issue, 
mouse bioassays are ongoing to compare the biological 
phenotype of this isolate relative to the other inoculated 
animals. In this study, differences in WB characteristics 
were also observed between the CNS and LRS from this 
animal and the ovine C-BSE control. However, this obser-
vation is consistent with previous reports for classical 
scrapie in which it has been speculated that this reflects 
tissue-specific differences in glycosylation [61, 62].
Pruritus and weight loss are common features in 
sheep experimentally infected with classical BSE [35]. 
Although weight loss was also recorded frequently in 
sheep infected with L-BSE, clear evidence of pruri-
tus was only seen in two ARQ/ARQ sheep whilst other 
sheep displayed the cataplectic form despite having the 
same prion protein genotype and being inoculated with 
the same inoculum. We have previously described similar 
divergent clinical syndromes in cattle [38, 63]. Testing the 
response to scratching as an indicator of pruritus was less 
useful in this study because a response was also seen in 
control animals and a positive scratch test was only con-
sidered to be indicative of pruritus if it was progressive 
(e.g. mere pressure on the back elicited a response) and 
accompanied by wool loss.
The display of cataplexy, defined as sudden and tran-
sient episodes of loss of motor tone, (often subsequent to 
intense emotion in humans) in most of the sheep, some-
times accompanied by apparent narcolepsy, was unusual 
because it preceded other neurological signs suggestive of 
a TSE, e.g. ataxia or tremor. Although collapsing episodes 
have been reported in classical scrapie, these are usually 
seen infrequently and often at late-stage disease, when 
other signs associated with scrapie (e.g. pruritus, abnormal 
behaviour) are already present. There are only a few reports 
of collapsing episodes in scrapie-affected sheep, triggered 
by stress [64–66] but they are usually accompanied by pru-
ritus, and not described as cataplexy-narcolepsy-like. There 
is a single report of cataplexy-narcolepsy in a lamb, which 
was associated with possibly impaired hypocretin function 
although the cause was not determined [67]. When initially 
presented with this sign in the first sheep, alternative diag-
noses such as cardiac or neuromuscular disorders were 
considered but excluded based on the absence of abnor-
malities in heart rate, rhythm and electrocardiogram and 
the abrupt onset of and recovery from the collapse.
Given the unusual clinical presentation of these animals, 
any such cases occurring naturally would be unlikely to 
present as TSE suspects. From a surveillance perspective, 
we would therefore be reliant on the rapid screening tests 
applied to fallen stock and/or healthy slaughter populations 
to detect such cases should they arise. It is reassuring that 
ovine L-BSE presents with positive test results using all cur-
rently approved screening and confirmatory tests, indicat-
ing that such cases would be detected as positive within 
routine active surveillance activities. It is also reassuring 
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that the existing confirmatory and discriminatory tests 
should identify these cases as unusual, and in some regards 
BSE-like in presentation, and they should result in referral 
for further investigation. However, caution should be exer-
cised if Western immunoblot is the only confirmatory test 
applied since it has been observed here that a low molecu-
lar mass suggestive of L-BSE may not always be observed. 
As these cases are also strongly detected by the N-terminal 
antibody they could present as very similar to scrapie in a 
field situation. For diagnostic purposes, when TSEs in small 
ruminants present a Western immunoblot profile that 
contains mixed characteristics of BSE and scrapie they are 
more readily visually identified as unusual when detection 
with an N-terminal antibody is reduced or absent. Other-
wise it can be more difficult to determine subtle differences 
in glycoform ratios and molecular mass migration, particu-
larly when the overall signal strength is high.
No cases presenting with such phenotypic characteris-
tics have been identified to date through the EU surveil-
lance systems. However, given the growing trend to view 
and treat atypical BSE differently from classical BSE, it is 
important to know that L-BSE in sheep could be detected, 
should relaxation of the current preventative measures 
applied to the ruminant feed chain occur in the future.
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Additional files
Additional file 1. Pruritic syndrome. Case 63/11 (ARQ/ARQ). This clip 
demonstrates progression in pruritic activity. Initially at 690 dpi there are 
some head movements in response to scratching (inconclusive scratch 
test response). The scratch test is clearly positive at 865 dpi when the 
sheep responded to scratching with lip licking and nibbling. There are no 
obvious gait abnormalities at this stage. Pruritic activity, such as rubbing 
and nibbling self, can be observed subsequently on CCTV from 840 dpi, 
which culminates in wool loss next to the tail head, indicated in the 
inset picture. Hind limb ataxia is now present at 949 dpi, which is most 
obvious when the sheep walks towards the other sheep, the wool loss 
subsequently remained but no skin lesions developed. Prior to cull at 956 
dpi, a positive scratch test can merely be elicited by applying pressure on 
the back.
Additional file 2. Cataplectic syndrome. Case 3/11 (ARQ/ARQ). When 
all sheep are penned up for spray marking, this sheep is seen collapsing 
briefly when restrained at 924 dpi. A similar response is elicited when the 
handler attempts to catch the sheep and although the animal is getting 
up immediately, general ataxia and low head carriage with apparent loss 
of muscle strength in the neck (“floppy neck”) is evident. CCTV images 
show lack of muscle tone when nudged by other sheep at the hay rack at 
954 dpi. Scratching of the back result in lip and head movements (posi-
tive scratch test) although there is no evidence of wool loss. Following a 
collapse after the examination, the sheep is seen lying in the corner as if 
asleep and rises shortly after stimulated by hand clapping.
Additional file 3. Seizure-like syndrome. Case 1591/10 (VRQ/ARQ). 
The sheep displays a positive scratch test at 746 dpi, the last examination 
prior to cull. At 803 dpi it is found dropping to the floor, and after walking 
slowly around the pen division it suddenly runs forward and drops to the 
floor, briefly vocalising, to end up in lateral position with all four limbs 
extended and trembling whilst the head is held between the front limbs. 
This episode only lasts a few seconds and the sheep gets up and runs 
away but drops down again at the edge of the pen division. Although the 
animal recovered from this episode it was culled on the same day.
Additional file 4. Antibody and glycoform ratios and molecular 
masses based on WB in Figure 4. A) Antibody detection ratios [Sha31 
(Figure 4A): P4 (Figure 4B)] for L-BSE in animals that are homozygous for 
alanine at codon 136 (samples 1-9). It can be seen that the ratios in all of 
the challenged animals are very similar to that obtained from the classi-
cal scrapie control. Ratios calculated using the 1 min exposure for both 
antibodies. B) Antibody detection ratios [Sha31 (Figure 4C): P4 (Figure 4D)] 
for L-BSE in animals that are homozygous or heterozygous for valine at 
codon 136 (samples 1-8). The ratios in all of the challenged animals are 
generally higher than those in animals homozygous for alanine at codon 
136 (A) but lower than that obtained from any of the bovine samples, with 
variable values sitting between the ovine classical scrapie and ovine BSE 
controls. This variability was not attributable to the codon 136 polymor-
phism, with samples 5, 6 and 8 being the homozygous animals. C) The 
glycoform profiles (relative quantity of the mono- versus di-glycosylated 
bands as observed in Figures 4A and 4C, using mAb Sha31). It can be seen 
that all of the sheep challenged with L-BSE have profiles which cluster 
with that of the bovine L-BSE donor, while bovine and ovine classical 
BSE are separate. D) Molecular masses for Sha31 based on Figure 4A. E) 
Molecular masses for Sha31 based on Figure 4C.
Additional file 5. Antibody and glycoform ratios and molecular 
masses based on WB in Figure 5. A) Antibody detection ratios (Sha31 
and P4 (Figure 5A)). All ratios are calculated using the 1 min exposure 
for both antibodies. The codon 136 alanine/valine heterozygous ovine 
L-BSE donor (sample 1) and similarly heterozygous recipients (samples 
2-6) are variable, but consistently lower than that for ovine classical BSE, 
and higher than the classical scrapie control. B) Antibody detection ratios 
[Sha31 and P4 (Figure 5B)]. All ratios are calculated using the 1 min expo-
sure for both antibodies. The codon 136 alanine homozygous ovine L-BSE 
donor (sample 1) and alanine/valine heterozygous recipients (samples 
2-6) are variable, but consistently lower than that for ovine classical BSE, 
and higher than the classical scrapie control. C) The glycoform profiles 
(relative quantity of the mono- versus di-glycosylated bands as observed 
in Figure 5A, using mAb Sha31). All the donor and recipient animals 
cluster with the classical scrapie control, and away from the ovine classi-
cal BSE. D) The glycoform profiles (relative quantity of the mono- versus 
di-glycosylated bands as observed in Figure 5B, using mAb Sha31). All the 
donor and recipient animals cluster with the classical scrapie control, and 
away from the ovine classical BSE. E) Molecular masses for Sha31 based on 
Figure 5A. F) Molecular masses for Sha31 based on Figure 5B.
Additional file 6. Antibody and glycoform ratios and molecular 
masses based on WB in Figure 6. A) Antibody detection ratios (Sha31 
(Figure 6A): P4 (Figure 6B)) show that the ovine BSE control samples 
(samples 1 (brain) and 2 (lymphoid tissue)) match the classical BSE control, 
whereas the lymphoid tissue (sample 3) and brain (sample 4) from the 
L-BSE challenged animal show ratios closer to that of the classical scrapie 
control. All ratios are calculated using the 1 min exposure for both 
antibodies. B) The glycoform profiles (relative quantity of the mono- ver-
sus di-glycosylated bands as observed in Figure 6A, using mAb Sha31) 
demonstrate that the ovine L-BSE samples (3 and 4) are quite distinct from 
both the ovine classical BSE samples (1 and 2) and the classical scrapie 
controls. C) Molecular masses for Sha31 based on Figure 6A.
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recipient sheep were provided by Dr Hugh Simmons (Defra project SE1931). 
Statistical advice was provided by Dr Angel Ortiz-Pelaez.
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